Although idarubicin and cytarabine in combination with clofarabine or fludarabine have similar response profiles in patients with newly diagnosed acute myeloid leukemia (AML), differences in survival were seen between the 2 groups in younger patients.
Variability in surface antigen expression patterns correlated to different outcomes in patients with normal karyotype acute myeloid leukemia (AML).
Timed sequential administration of busulfan may represent a more efficacious approach to the treatment of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Allogeneic stem-cell transplant was found to improve patient outcomes, regardless of age and induction regimen.
Differentiation syndrome, a side effect of enasidenib therapy, can often be managed with pharmacologic interventions and, if necessary, dose interruption.
Although two-thirds of patients with newly diagnosed acute myeloid leukemia (AML) are tested for recurrent mutations, most do not receive the complete panel of guideline-recommended tests.
The majority of newly diagnosed patients with acute myeloid leukemia (AML) were found to be minimal residual disease (MRD)-negative after induction with a crenolanib-containing regimen.